Retatrutide

Retatrutide is an experimental, once-weekly injectable triple-agonist medication (GLP-1, GIP, and Glucagon receptors) developed by Eli Lilly for obesity and Type 2 diabetes. Currently in Phase 3 trials, it has shown superior weight loss (up to 24–28% in studies) compared to current drugs, alongside improved fat metabolism, with potential approval following early 2026.